{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:57:47Z","timestamp":1788785867971,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Center for Tumor Diseases"},{"name":"Clinical Neuroscience and is funded by the Emmy-Noether Programme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Meningiomas are the most common adult brain tumors. While homozygous deletions of CDKN2A\/B are linked to early recurrence and hence serve as CNS WHO grade 3 criterion, the clinical impact of hemizygous deletions remains unclear\u2014especially since distinguishing between hemi- and homozygous losses can be technically challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DNA methylation data, copy-number, and mutation data were evaluated on a multicenter cohort of 970 meningiomas. Each sample\u2019s CDKN2A\/B status was manually classified by visual inspection in relation to whole chromosomal losses and gains in the copy number profile generated from global methylation array data in relation to other copy number events. Progression probabilities were determined using the Kaplan-Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 970 meningiomas, n\u2009=\u200930 had homozygous, n\u2009=\u2009114 hemizygous (n\u2009=\u200931 segmental; n\u2009=\u200983 focal), and n\u2009=\u2009826 CDKN2A\/B balanced status. In cases with hemizygous deletions in general, an association with increased progression risk compared to balanced cases was observed, although this did not reach statistical significance (log-rank P\u2009=\u2009.074; HR\u2009=\u20091.36, 95% CI [0.97, 1.90]; P\u2009=\u2009.07). However, segmental hemizygous losses were linked to a significantly worse prognosis (log-rank P\u2009=\u2009.0023), but focal hemizygous deletions were not (log-rank P\u2009=\u2009.523). Segmental hemizygous CDKN2A\/B deletions were more frequently associated with a higher amount of high-risk copy number variations than focal losses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that hemizygous CDKN2A\/B deletions overall do not confer worse risks for progression in meningiomas. The signal for segmental deletions may not be locus-specific but just one representation of the generally instable genome of aggressive meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag024","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:48:30Z","timestamp":1770209310000},"page":"1209-1219","source":"Crossref","is-referenced-by-count":4,"title":["The prognostic impact of\n                    <i>CDKN2A\/B<\/i>\n                    hemizygous deletions in meningioma"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-1784","authenticated-orcid":false,"given":"Franziska M","family":"Ippen","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]},{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, German Cancer Research Center (DKFZ) , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Patel","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5067-3009","authenticated-orcid":false,"given":"Dennis","family":"Friedel","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]},{"name":"Faculty of Bioscience, Heidelberg University , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6021","authenticated-orcid":false,"given":"Philipp","family":"Sievers","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Acker","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Giessen , Giessen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Snuderl","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York University School of Medicine , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Brandner","sequence":"additional","affiliation":[{"name":"Department of Neurodegeneration, Institute of Neurology, University College London , London,","place":["UK"]},{"name":"Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybren L N","family":"Maas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]},{"name":"Department of Pathology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas v","family":"Deimling","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ) , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya Linda","family":"Bi","sequence":"additional","affiliation":[{"name":"Mass General Brigham, Harvard Medical School , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail K","family":"Suwala","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026051916115850000_noag024-B1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026051916115850000_noag024-B2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":":","key":"2026051916115850000_noag024-B3","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"JNCIJ"},{"key":"2026051916115850000_noag024-B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2026051916115850000_noag024-B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s40478-023-01690-y","article-title":"CDKN2A\/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data","volume":"11","author":"Wach","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"2026051916115850000_noag024-B6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026051916115850000_noag024-B7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00401-023-02543-7","article-title":"Even heterozygous loss of CDKN2A\/B greatly accelerates recurrence in aggressive meningioma","volume":"145","author":"Khan","year":"2023","journal-title":"Acta Neuropathol"},{"key":"2026051916115850000_noag024-B8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00401-023-02571-3","article-title":"Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas","volume":"146","author":"Wang","year":"2023","journal-title":"Acta Neuropathol"},{"key":"2026051916115850000_noag024-B9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of Central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"2026051916115850000_noag024-B10","doi-asserted-by":"publisher","first-page":"e13132","DOI":"10.1111\/bpa.13132","article-title":"Clinical implementation of integrated molecular-morphologic risk prediction for meningioma","volume":"33","author":"Hielscher","year":"2023","journal-title":"Brain Pathol"},{"key":"2026051916115850000_noag024-B11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00401-015-1519-8","article-title":"Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets","volume":"131","author":"Sahm","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026051916115850000_noag024-B12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"2026051916115850000_noag024-B13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"2026051916115850000_noag024-B14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark","year":"2016","journal-title":"Nat Genet"},{"key":"2026051916115850000_noag024-B15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026051916115850000_noag024-B16","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026051916115850000_noag024-B17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"key":"2026051916115850000_noag024-B18","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026051916115850000_noag024-B19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/ng.2760","article-title":"Pan-cancer patterns of somatic copy number alteration","volume":"45","author":"Zack","year":"2013","journal-title":"Nat Genet"},{"key":"2026051916115850000_noag024-B20","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/neuonc\/noad095","article-title":"Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas","volume":"25","author":"Kocakavuk","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026051916115850000_noag024-B21","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1038\/s41467-025-61063-y","article-title":"Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification","volume":"16","author":"Nguyen","year":"2025","journal-title":"Nat Commun"},{"key":"2026051916115850000_noag024-B22","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/s41467-025-60734-0","article-title":"Distribution of copy number alterations and impact of chromosome arm call thresholds for meningioma","volume":"16","author":"Patel","year":"2025","journal-title":"Nat Commun"},{"key":"2026051916115850000_noag024-B23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00401-023-02544-6","article-title":"Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas","volume":"145","author":"Tang","year":"2023","journal-title":"Acta Neuropathol"},{"key":"2026051916115850000_noag024-B24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41588-024-01747-1","article-title":"Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution","volume":"56","author":"Lucas","year":"2024","journal-title":"Nat Genet"},{"key":"2026051916115850000_noag024-B25","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med"},{"key":"2026051916115850000_noag024-B26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"2026051916115850000_noag024-B27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026051916115850000_noag024-B28","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1038\/s41591-024-03167-4","article-title":"Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2026051916115850000_noag024-B29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/neuonc\/nov285","article-title":"Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade","volume":"18","author":"Hwang","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026051916115850000_noag024-B30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","article-title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","volume":"26","author":"Groff","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag024\/66851747\/noag024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1209\/66851747\/noag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1209\/66851747\/noag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:12:04Z","timestamp":1779221524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/5\/1209\/8472729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag024","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,11]]}}}